Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-Plasma peptidomes from nasopharyngeal cancer patients for example

Clinical Biochemistry

Volumn 39, Issue 12, 2006, Pages 1144-1151

  Chang, Joseph Tung Chieh ^a   Chen, Li Chiu ^b   Wei, Shang Yi ^b   Chen, Yin Ju ^b   Wang, Hung Ming ^a   Liao, Chun Ta ^a   Chen, I How ^a   Cheng, Ann Joy ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Complement 3; MALDI TOF; Nasopharyngeal cancer; Plasma proteome; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COPPER; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG USE; FEMALE; HEPARINIZATION; HUMAN; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NASOPHARYNX CANCER; PLASMA; PRIORITY JOURNAL; PROTEOMICS; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PEPTIDE MAPPING; PROTEOME; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33751520049     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.08.010     Document Type: Article

References (34)

1. Banks R.E., Dunn M.J., Hochstrasser D.F., Sanchez J.C., Blackstock W., Pappin D.J., et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 356 (2000) 1749-1756
2. Seliger B., and Kellner R. Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics 2 (2002) 1641-1651
3. Steel L.F., Shumpert D., Trotter M., Seeholzer S.H., Evans A.A., London W.T., et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3 (2003) 601-609
4. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48 (2002) 1296-1304
5. Chapman K. The ProteinChip biomarker system from ciphergen biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem. Soc. Trans. 30 (2002) 82-87
6. Merchant M., and Weinberger S.R. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21 (2000) 1164-1177
7. Conrads T.P., Zhou M., Petricoin III E.F., Liotta L., and Veenstra T.D. Cancer diagnosis using proteomic patterns. Expert Rev. Mol. Diagn. 34 (2003) 411-420
8. Issaq H.J., Veenstra T.D., Conrads T.P., and Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292 (2002) 587-592
9. Xiao Z., Adam B.L., Cazares L.H., Clements M.A., Davis J.W., Schellhammer P.F., et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61 (2001) 6029-6033
10. Shiwa M., Nishimura Y., Wakatabe R., Fukawa A., Arikuni H., Ota H., et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem. Biophys. Res. Commun. 309 (2003) 18-25
11. Wellmann A., Wollscheid V., Lu H., Ma Z.L., Albers P., Schutze K., et al. Analysis of microdissected prostate tissue with ProteinChip arrays-A way to new insights into carcinogenesis and to diagnostic tools. Int. J. Mol. Med. 9 (2002) 341-347
12. Zheng Y., Xu Y., Ye B., Lei J., Weinstein M.H., O'Leary M.P., et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98 (2003) 2576-2582
13. Kozak K.R., Amneus M.W., Pusey S.M., Su F., Luong M.N., Luong S.A., et al. Identification of biomarkers for ovarian cancer using strong anion-exchange Protein Chips: potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12343-12348
14. Lewczuk P., Esselmann H., Groemer T.W., Bibl M., Maler J.M., Steinacker P., et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol. Psychiatry 55 (2004) 524-530
15. Li J., White N., Zhang Z., Rosenzweig J., Mangold L.A., Partin A.W., et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J. Urol. 171 (2004) 1782-1787
16. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
17. Rogers M.A., Clarke P., Noble J., Munro N.P., Paul A., Selby P.J., et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 63 (2003) 6971-6983
18. Cheng A.J., Chen L.C., Chien K.Y., Chen J.Y., Chang J.TC., Wang H.M., et al. Oral cancer plasma tumor marker identified with bead-based affinity fractionated proteomic technology. Clin. Chem. 51 (2005) 2236-2244
19. Weish J.B., Sapinoso L.M., Kern S.G., Brown D.A., Liu T., Bauskin A.R., et al. Largely scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3410-3415
20. Petricoin III E.F., Ardekani A.M., Hitt B.A., Levine P., Fusaro V.A., Steinberg S., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-575
21. Powell K. Proteomics delivers on promise of cancer biomarkers. Nat. Med. 9 (2003) 980
22. Isaaq H.J., Conrads T.P., Prieto D.A., and Tirumalai R. Veenstra, SELDI-TOF MS for diagnostic proteomics. Anal. Chem. 75 (2003) 149A-155A
23. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol. Cell Proteomics 3 (2004) 367-378
24. Moomen J.M., Li D., Xiao L.C., Liu T.C., Copmbes K.R., Abbruzzese J., et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 4 (2005) 972-981
25. Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., et al. Overview of the HUPO plasma proteome project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5 (2005) 3226-3245
26. Fracalanza S., Prayer-Galetti T., Pinto F., Navaglia F., Sacco E., Ciaccia M., et al. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination. Urol. Int. 75 (2005) 57-61
27. Panzuto F., Severi C., Cannizzaro R., Falconi M., Angeletti S., Pasquali A., et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J. Endocrinol. Invest. 27 (2004) 6-11
28. Lin Y.C., Chou Y.HW., Liao I.C., and Cheng A.J. The expression of mammaglobin mRNA in peripheral blood of metastatic breast cancer patients as an adjunct to serum tumor markers. Cancer Lett. 191 (2003) 93-99
29. Cole D.S., and Morgan B.P. Beyond lysis: how complement influences cell fate. Clin. Sci. (Lond) 104 (2003) 455-466
30. Harrison R.A., Farries T.C., Northrop F.D., Lachmann P.J., and Davis A.E. Structure of C3f, a small peptide specifically released during inactivation of the third component of complement. Complement 5 (1988) 27-32
31. Rozanov D.V., Savinov A.Y., Golubkov V.S., Postnova T.I., Remacle A., Tomlinson S., et al. Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system. J. Biol. Chem. 279 (2004) 46551-46557
32. Hakulinen J., Junnikkala S., Sorsa T., and Meri S. Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur. J. Immunol. 34 (2004) 2620-2629
33. Steel L.F., Shumpert D., Trotter M., Seeholzer S.H., Evans A.A., London W.T., et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3 (2003) 601-609
34. Oner F., Savas I., and Numanoglu N. Immunoglobulins and complement components in patients with lung cancer. Tuberk Toraks 52 (2004) 19-23